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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER1Bleeding Avoidance StrategiesHarold L. Dauerman, Sunil V. Rao, Frederic S. Resnic, Robert J. Applegate
Bleeding complications after coronary intervention are associated with increased morbidity
and mortality. Dauerman and colleagues review several lines of evidence that suggest a recent
decline in percutaneous coronary intervention bleeding complications. The efficacy, safety,
and/or practicality of 3 key bleeding avoidance strategies are reviewed: procedural (radial
artery approach, safe zone arteriotomy), pharmacological (multiple agents), and technological
(vascular closure devices) approaches to improved access. There remain several areas of
controversy warranting cautious clinical approaches, and there is a need for future randomized
clinical trials in this area to optimize bleeding avoidance strategies.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY11EES Superior to PES at 2 Years From the COMPARE TrialPieter C. Smits, Elvin Kedhi, Kees-Jan Royaards, Kaiyum Sheik Joesoef, Jochem Wassing,
Tessa A. M. Rademaker-Havinga, Eugene McFadden
Smits and colleagues present the 2-year results of the COMPARE trial, which randomized
an all-comer population undergoing percutaneous coronary intervention to either an
everolimus-eluting stent (EES) or a paclitaxel-eluting stent (PES). At 2 years, the primary
composite of all death, nonfatal myocardial infarction (MI), and target vessel revascularization
(TVR) occurred in 9.0% of EES and 13.7% of PES patients, driven by lower rates of MI,
TVR, and stent thrombosis. Differences significantly increased between 1 and 2 years of
follow-up. At 2 years, EES maintained superiority over PES, with increasing differences in
safety and efficacy endpoints.(continued on page A-23)
JUNE 28, 2011 (continued) A-23INTERVENTIONAL CARDIOLOGY19Sustained Benefits of EES Over PES at 2 Years in the SPIRIT IV TrialGregg W. Stone, Ali Rizvi, Krishnankutty Sudhir, William Newman, Robert J. Applegate,
Louis A. Cannon, James T. Maddux, Donald E. Cutlip, Charles A. Simonton, Poornima Sood,
Dean J. Kereiakes, for the SPIRIT IV Investigators
In the SPIRIT IV trial, patients with noncomplex lesions undergoing percutaneous coronary
intervention were randomized to an everolimus-eluting stent (EES) or a paclitaxel-eluting
stent (PES). This report details the outcomes at 2 years. EES were associated with lower
rates of the primary endpoint and target lesion failure, as well as lower rates of myocardial
infarction and stent thrombosis independently. Between 1 and 2 years, there were no
significant differences in adverse event rates between the 2 stent types. In the large-scale,
prospective, multicenter, randomized SPIRIT IV trial, the benefits of EES compared with
PES present at 1 year were sustained at 2 years.Editorial Comment: Fernando Alfonso, Cristina Fernandez, p. 26CORONARY ARTERY DISEASE30Variant of IRS-1 Gene Affects Response to Clopidogrel in Diabetic PatientsDominick J. Angiolillo, Esther Bernardo, Martina Zanoni, David Vivas, Piera Capranzano,
Giovanni Malerba, Davide Capodanno, Paola Prandini, Alessandra Pasquali, Elisabetta Trabetti,
Manel Sabaté, Pilar Jimenez-Quevedo, Jose L. Ferreiro, Masafumi Ueno, Theodore A. Bass,
Pier Franco Pignatti, Antonio Fernandez-Ortiz, Carlos Macaya
Human platelets are targets of insulin through the insulin receptor substrate-1 (IRS-1).
Angiolillo and colleagues assessed the association between genetic variants of the IRS-1 gene,
platelet function, and long-term outcomes in patients with diabetes and stable coronary artery
disease (CAD) who were on aspirin and clopidogrel. Individuals with high platelet reactivity
were more frequent among carriers of the C allele (GC and CC genotypes; 20% of
population) of the rs956115 marker, and these patients were at a higher risk of major adverse
cardiovascular events. The results were externally validated in another cohort of diabetic
patients, but no relationship was seen in nondiabetic patients. These results help to explain
the relationship between diabetes and high platelet reactivity.(continued on page A-26)
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EHEART RHYTHM DISORDERS40Reconstituted HDL Shortens Cardiac RepolarizationHester M. Den Ruijter, Remco Franssen, Arie O. Verkerk, Diederik F. van Wijk, Stefan F. Vaessen,
Adriaan G. Holleboom, Johannes H. Levels, Tobias Opthof, Rattapong Sungnoon, Erik S. Stroes,
Jan Albert Kuivenhoven, Ruben Coronel
High-density lipoprotein cholesterol (HDL-C) is inversely associated with sudden death.
Den Ruijter and colleagues hypothesized that HDL-C shortens cardiac repolarization.
Cardiac repolarization was studied with the patch clamp technique from isolated rabbit
cardiomyocytes and in humans. Reconstituted high-density lipoprotein (HDL) as well as
purified human apolipoprotein A-I shortened repolarization of isolated rabbit cardiomyocytes
by 25%. Reconstituted HDL infusion shortened the QT interval in human subjects. These
ata provide evidence for a novel mechanism of HDL to reduce the risk of sudden cardiac
eath.ditorial Comment: Paulus Kirchhof, Larissa Fabritz, p. 45HEART RHYTHM DISORDERS48Arrhythmogenic Myocarditis Due to Myocardial Tuberculosis or Cardiac SarcoidosisAjit Thachil, Johann Christopher, B. K. S. Sastry, Kavitha Nallapa Reddy, Vijaya K. Tourani, Ashfaq
Hassan, Bhupathiraju Soma Raju, Calambur Narasimhan
Thachil and colleagues describe a syndrome of sustained monomorphic ventricular tachycardia
(SMVT) with mediastinal adenopathy. Patients without obstructive coronary artery disease
and normal ventricular function presenting with SMVT underwent computed tomography,
magnetic resonance imaging, and positron emission tomographic studies; all patients had
noncaseating granulomas in their mediastinal lymph nodes. Evidence of tuberculosis was
present in 79%. Patients had multiple arrhythmias despite antiarrhythmic drugs and/or
radiofrequency ablation. Addition of disease-specific therapy (for either tuberculosis or
sarcoidosis) abolished further recurrences in 64% of patients. This report suggests that
sarcoidosis and tuberculosis can cause SMVT without obvious myocardial involvement but
will respond to disease-specific therapy.BIOMARKERS56NT-proBNP Is a Better Predictor of Cardiovascular Risk Than CRPS. Goya Wannamethee, Paul Welsh, Gordon D. Lowe, Vilmundur Gudnason, Emanuele Di Angelantonio,
Lucy Lennon, Ann Rumley, Peter H. Whincup, Naveed Sattar
Wannamethee and colleagues compared the predictive capabilities of N-terminal pro–B-type
natriuretic peptide (NT-proBNP) and C-reactive protein (CRP) for predicting cardiovascular
disease (CVD) risk in older men. In a prospective study of almost 4,000 men age 60 to 79
years followed up for a mean of 9 years, NT-proBNP was significantly associated with risk of
all major CVD outcomes. NT-proBNP was more strongly associated with CVD outcomes
than CRP, particularly among patients with pre-existing CVD. Inclusion of NT-proBNP in
a Framingham-based model yielded significant improvement in C-statistics and net
reclassification improvement. NT-proBNP, but not CRP, improves prediction of major CVD
events in older men.
(continued on page A-28)
JUNE 28, 2011 (continued) A-28NWORKS IN PROGRESS WORKS IN PROGRESS
65ovel Echocardiographic Technique Measures
Myocardial Contractility Using Shear Wave ImagingMathieu Pernot, Mathieu Couade, Philippe Mateo, Bertrand Crozatier, Rodolphe Fischmeister,
Mickaël Tanter
Pernot and colleagues describe a novel approach for measuring myocardial stiffness based on
shear wave imaging (SWI). SWI is an ultrasound-based technique that uses multiwave
imaging to combine 2 different waves: one (shear wave) providing stiffness contrast, and
another (ultrasound) providing millimeter spatial resolution. SWI was performed in
Langendorff-perfused isolated rat hearts. Myocardial stiffness was measured with SWI and
compared with isovolumic systolic pressure at rest, during administration of isoproterenol, and
with calcium overload. This report shows that myocardial stiffness can be measured
throughout the cardiac cycle using SWI.PRE-CLINICAL RESEARCH PRE-CLINICAL RESEARCH73Blocking Mitochondrial Oxidative Stress Prevents Hypertensive CardiomyopathyDao-Fu Dai, Tony Chen, Hazel Szeto, Madeline Nieves-Cintro´n, Vassily Kutyavin, Luis F. Santana,
Peter S. Rabinovitch
Dai and colleagues investigated the effect of reducing mitochondrial reactive oxygen species in
a mouse model where hypertension is produced by the continuous infusion of angiotensin II
(Ang II). Continuous administration of Ang II increased both systolic and diastolic blood
pressure, and this was not affected by the mitochondrial-targeted antioxidant peptide SS-31.
SS-31 did attenuate NOX4 up-regulation and mitochondrial oxidative damage, and it
prevented apoptosis. It also ameliorated Ang II induced cardiac hypertrophy, diastolic
dysfunction, and fibrosis.
Editorial Comment: Christoph Maack, Michael Böhm, p. 83
